× Thanks for reading! Log in to continue. Enjoy more articles by logging in or creating a free account. No credit card required. Log in Sign up {{featured_button_text}}

Madison-based Exact Sciences on Tuesday announced pay cuts, furloughs and staff reductions to address a large decrease in demand for the company’s cancer screening services during the COVID-19 pandemic.

From March 15 to March 31, Exact Sciences saw a 36% decrease from last year in orders for its stool test called Cologuard, which checks for blood and DNA biomarkers that indicate possible colorectal cancer, according to a report released by the company Tuesday.

And during the first 20 days of April, Cologuard orders dropped even more, with a 63% decrease as compared with the same period last year.

Although preliminary data show revenue for the first three months of the year was up from last year — with a total of $348 million this year compared with $162 million from January to March of 2019 — Exact Sciences said it expects a “widespread decrease in preventative services,” including prostate cancer screenings and mammograms.

“Due to social distancing, stay-at-home orders, and other actions taken in response to COVID-19, there has been a significant and widespread decline in standard wellness visits and preventive services,” Exact Sciences said in the report.